{
    "id": 60083,
    "name": "immune system cancer",
    "source": "DOID",
    "definition": "An organ system cancer located_in the immune system that is characterized by uncontrolled cellular proliferation in organs of the immune system. [url:http\\://en.wikipedia.org/wiki/Immune_system]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0060083",
    "evidence": [
        {
            "id": 9556,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Afuresertib (GSK2110183) in patients with Langerhans cell histiocytosis resulted in an overall response rate of 33% in treatment-naive patients and 28% in patients with refractory disease (PMID: 27804235).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 625,
                "therapyName": "Afuresertib",
                "synonyms": null
            },
            "indication": {
                "id": 60083,
                "name": "immune system cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7270,
                    "pubMedId": 27804235,
                    "title": "A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27804235"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        
    ]
}